Highlighted for strong 1-year performance (40.88% return) and targeted biotech growth strategy, but offset by higher expense ratio (0.58%), concentrated holdings (31 stocks), and significantly higher volatility (37.84% max drawdown). Suitable only for risk-tolerant investors.
Articles that tag PBE but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology